Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00297973
Status:
COMPLETED
Last Update Posted:
2021-01-27
First Post:
2006-02-27
Brief Title:
Cardiovascular Risk Assessment in Patients Treated With Caduet
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
Cardiovascular Risk Assessment In Patients With Hypertension And At Least Three Other Risk Factors Treated With Caduet Compared To Usual Care The Right Study
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIGHT
Brief Summary:
Compare the reduction in Framinghams predicted 10-year risk of a coronary event 6 in patients with hypertension and at least three other cardiovascular risk factors including diabetic patients seen in private practice and randomized to either Caduet or usual care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None